Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 study of CR-001 in solid tumors.

Next Previous
Trial Profile

A phase 1 study of CR-001 in solid tumors.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CR-001-Crescent Biopharma (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 16 Jun 2025 According to Crescent Biopharma Media Release, Company anticipate dosing patients of this study in early 2026.
  • 10 Apr 2025 New trial record
  • 03 Apr 2025 According to Crescent Biopharma Media Release, company remains on track to submit an Investigational New Drug (IND) application for its lead program, CR-001, a tetravalent PD-1 x VEGF bispecific antibody, in the fourth quarter of 2025, with initial clinical data from a Phase 1 trial in patients with solid tumors expected in the second half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top